We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has EUROFINS SCIENT (ERFSF) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has EUROFINS SCIENT (ERFSF - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
EUROFINS SCIENT is one of 1005 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. EUROFINS SCIENT is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ERFSF's full-year earnings has moved 2.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ERFSF has returned 3.3% so far this year. In comparison, Medical companies have returned an average of 1.2%. This means that EUROFINS SCIENT is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Abbott (ABT - Free Report) . The stock has returned 16.4% year-to-date.
In Abbott's case, the consensus EPS estimate for the current year increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, EUROFINS SCIENT belongs to the Medical Services industry, a group that includes 58 individual stocks and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 2.8% so far this year, so ERFSF is performing better in this area.
Abbott, however, belongs to the Medical - Products industry. Currently, this 81-stock industry is ranked #173. The industry has moved +7% so far this year.
Investors with an interest in Medical stocks should continue to track EUROFINS SCIENT and Abbott. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has EUROFINS SCIENT (ERFSF) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has EUROFINS SCIENT (ERFSF - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
EUROFINS SCIENT is one of 1005 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. EUROFINS SCIENT is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ERFSF's full-year earnings has moved 2.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ERFSF has returned 3.3% so far this year. In comparison, Medical companies have returned an average of 1.2%. This means that EUROFINS SCIENT is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Abbott (ABT - Free Report) . The stock has returned 16.4% year-to-date.
In Abbott's case, the consensus EPS estimate for the current year increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, EUROFINS SCIENT belongs to the Medical Services industry, a group that includes 58 individual stocks and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 2.8% so far this year, so ERFSF is performing better in this area.
Abbott, however, belongs to the Medical - Products industry. Currently, this 81-stock industry is ranked #173. The industry has moved +7% so far this year.
Investors with an interest in Medical stocks should continue to track EUROFINS SCIENT and Abbott. These stocks will be looking to continue their solid performance.